Drugs / [S,S]-Reboxetine
[S,S]-Reboxetine
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00800956 | Jan → Feb 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00809289 | Dec 2008 → Jul 2009 | fibromyalgia | Pfizer | Completed | No outcome recorded |
| Phase 212 trials · 1 met primary | ||||||
| Phase 2 | NCT00752505 | Aug 2008 → Jun 2009 | fibromyalgia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00625833 | Dec 2007 → Nov 2008 | diabetic neuropathy | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00562055 | Nov 2007 → ? | attention deficit-hyperactivity disorder | Pfizer | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00354094 | Nov 2006 → Oct 2007 | — | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00334685 | Aug 2006 → Oct 2007 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00357825 | Aug 2006 → Mar 2007 | — | Pfizer | Completed | Met primary |
| Phase 2 | NCT00353808 | Jul 2006 → Oct 2007 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00348894 | Jul 2006 → Oct 2007 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00288652 | Mar 2006 → Feb 2007 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00141128 | Dec 2005 → Jun 2006 | female stress incontinence | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00636246 | Jun 2004 → Aug 2005 | major depressive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00143442 | Dec 2003 → Oct 2004 | — | Pfizer | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT00796601 | May 2009 → May 2010 | fibromyalgia | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00754221 | May 2008 → May 2009 | fibromyalgia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00612170 | Dec 2007 → May 2009 | fibromyalgia | Pfizer | Completed | Met primary |
| Phase 3 | NCT00607256 | Oct 2007 → May 2009 | fibromyalgia | Pfizer | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00444548 | May → Jul 2007 | — | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [S,S]-reboxetine | “Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg...” NCT00636246 ↗14“Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care” NCT00348894 ↗ |
| Known as | Esreboxetine | “17 women with stress urinary incontinence or mixed urinary incontinence received 4 mg esreboxetine or placebo for 7 to 9 days followed by a washout period before crossing over...” PMID 19375093 ↗ Apr 2009 |
| Known as | PNU-165442G | “A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN).” NCT00354094 ↗4“A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.” NCT00752505 ↗ “A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia” NCT00754221 ↗ “A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia” NCT00607256 ↗ “Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care” NCT00348894 ↗ |
| Route | Oral | “[S,S]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks” NCT00334685 ↗ |